

Michael Millward

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3230596/publications.pdf>

Version: 2024-02-01

102
papers

8,501
citations

159585

30
h-index

45317

90
g-index

105
all docs

105
docs citations

105
times ranked

10719
citing authors

#	ARTICLE	IF	CITATIONS
1	First-in-human phase 1 study of budigalimab, an anti-PD-1 inhibitor, in patients with non-small cell lung cancer and head and neck squamous cell carcinoma. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 417-431.	4.2	6
2	Detection of clinical progression through plasma ctDNA in metastatic melanoma patients: a comparison to radiological progression. <i>British Journal of Cancer</i> , 2022, 126, 401-408.	6.4	18
3	Phase 1A/1B dose-escalation and -expansion study to evaluate the safety, pharmacokinetics, food effects and antitumor activity of pamiparib in advanced solid tumours. <i>British Journal of Cancer</i> , 2022, 126, 576-585.	6.4	7
4	Evaluation of PD-L1 expression on circulating tumour cells in small-cell lung cancer. <i>Translational Lung Cancer Research</i> , 2022, 11, 440-451.	2.8	12
5	Sunvozertinib, a Selective EGFR Inhibitor for Previously Treated Non-EGFR Exon 20 Insertion Mutations. <i>Cancer Discovery</i> , 2022, 12, 1676-1689.	9.4	30
6	Antitumor activity of sunvozertinib in NSCLC patients with EGFR Exon20 insertion mutations after platinum and anti-PD(L)1 treatment failures.. <i>Journal of Clinical Oncology</i> , 2022, 40, 9015-9015.	1.6	6
7	Assessment of tissue and blood tumor mutational burden in patients with melanoma using a 523-gene clinical assay.. <i>Journal of Clinical Oncology</i> , 2022, 40, e21570-e21570.	1.6	0
8	Autoantibodies as potential biomarkers of immune-related adverse events in patients with advanced cutaneous melanoma treated with immune checkpoint inhibitors.. <i>Journal of Clinical Oncology</i> , 2022, 40, 9536-9536.	1.6	0
9	A phase 1 dose-escalation study of the ABN401 (c-MET inhibitor) in patients with solid tumors.. <i>Journal of Clinical Oncology</i> , 2022, 40, 3105-3105.	1.6	0
10	A phase 1 dose-escalation study to investigate the safety, efficacy, pharmacokinetics, and pharmacodynamic activity of CLN-619 (anti-MICA/MICB antibody) alone and in combination with pembrolizumab in patients with advanced solid tumors.. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS2688-TPS2688.	1.6	1
11	Low-coverage whole-genome sequencing of extracellular vesicle-associated DNA in patients with metastatic cancer. <i>Scientific Reports</i> , 2021, 11, 4016.	3.3	6
12	Patient human leukocyte antigen (HLA) genotype may predict response to anti-programmed death receptor 1 (anti-PD1) in advanced melanoma.. <i>Journal of Clinical Oncology</i> , 2021, 39, e21512-e21512.	1.6	0
13	Increased interdigitation zone visibility on optical coherence tomography following systemic fibroblast growth factor receptor tyrosine kinase inhibitor anticancer therapy. <i>Clinical and Experimental Ophthalmology</i> , 2021, 49, 579-590.	2.6	7
14	Adjuvant nivolumab for stage III/IV melanoma: evaluation of safety outcomes and association with recurrence-free survival. , 2021, 9, e003188.		12
15	Safety, pharmacokinetics, and efficacy of budigalimab with rovalpituzumab tesirine in patients with small cell lung cancer. <i>Cancer Treatment and Research Communications</i> , 2021, 28, 100405.	1.7	6
16	Dynamic Landscape of Extracellular Vesicle-Associated Proteins Is Related to Treatment Response of Patients with Metastatic Breast Cancer. <i>Membranes</i> , 2021, 11, 880.	3.0	4
17	Combined ipilimumab and nivolumab first-line and after BRAF-targeted therapy in advanced melanoma. <i>Pigment Cell and Melanoma Research</i> , 2020, 33, 358-365.	3.3	51
18	Long-term outcomes in patients with BRAF V600-mutant metastatic melanoma receiving dabrafenib monotherapy: Analysis from phase 2 and 3 clinical trials. <i>European Journal of Cancer</i> , 2020, 125, 114-120.	2.8	47

#	ARTICLE	IF	CITATIONS
19	A phase II trial of single oral FGF inhibitor, AZD4547, as second or third line therapy in malignant pleural mesothelioma. <i>Lung Cancer</i> , 2020, 140, 87-92.	2.0	21
20	PD-L1 Expression on Circulating Tumor Cells May Be Predictive of Response to Pembrolizumab in Advanced Melanoma: Results from a Pilot Study. <i>Oncologist</i> , 2020, 25, e520-e527.	3.7	54
21	Circulating Tumor DNA Predicts Outcome from First-, but not Second-line Treatment and Identifies Melanoma Patients Who May Benefit from Combination Immunotherapy. <i>Clinical Cancer Research</i> , 2020, 26, 5926-5933.	7.0	41
22	Circulating Tumour DNA in Advanced Melanoma Patients Ceasing PD1 Inhibition in the Absence of Disease Progression. <i>Cancers</i> , 2020, 12, 3486.	3.7	10
23	Adjuvant nivolumab versus ipilimumab in resected stage IIIb and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial. <i>Lancet Oncology</i> , 2020, 21, 1465-1477.	10.7	330
24	The Prognostic Impact of Circulating Tumour DNA in Melanoma Patients Treated with Systemic Therapies Beyond BRAF Mutant Detection. <i>Cancers</i> , 2020, 12, 3793.	3.7	12
25	Tumour PD-L1 Expression in Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis. <i>Cells</i> , 2020, 9, 2393.	4.1	31
26	Detection of Low-level EGFR c.2369 G>T (p.Thr790Met) Resistance Mutation in Pre-treatment Non-small Cell Lung Carcinomas Harboring Activating EGFR Mutations and Correlation with Clinical Outcomes. <i>Pathology and Oncology Research</i> , 2020, 26, 2371-2379.	1.9	4
27	Results of a randomized, double-blind phase II clinical trial of NY-ESO-1 vaccine with ISCOMATRIX adjuvant versus ISCOMATRIX alone in participants with high-risk resected melanoma. , 2020, 8, e000410.		21
28	<p>A First-in-Human Dose Finding Study of Camrelizumab in Patients with Advanced or Metastatic Cancer in Australia</p>. <i>Drug Design, Development and Therapy</i> , 2020, Volume 14, 1177-1189.	4.3	21
29	Role of Serum Vascular Endothelial Growth Factor (VEGF) as a Potential Biomarker of Response to Immune Checkpoint Inhibitor Therapy in Advanced Melanoma: Results of a Pilot Study. <i>Frontiers in Oncology</i> , 2020, 10, 1041.	2.8	12
30	Detection and prognostic role of heterogeneous populations of melanoma circulating tumour cells. <i>British Journal of Cancer</i> , 2020, 122, 1059-1067.	6.4	41
31	A multicenter study of thromboembolic events among patients diagnosed with ROS1-rearranged non-small cell lung cancer. <i>Lung Cancer</i> , 2020, 142, 34-40.	2.0	27
32	A comparative study of extracellular vesicle-associated and cell-free DNA and RNA for HPV detection in oropharyngeal squamous cell carcinoma. <i>Scientific Reports</i> , 2020, 10, 6083.	3.3	28
33	Detection of BRAF splicing variants in plasma-derived cell-free nucleic acids and extracellular vesicles of melanoma patients failing targeted therapy therapies. <i>Oncotarget</i> , 2020, 11, 4016-4027.	1.8	6
34	Predictive value of PD-L1 and other clinical factors for chemoimmunotherapy in advanced non-small-cell lung cancer. <i>Future Oncology</i> , 2019, 15, 2371-2383.	2.4	4
35	Is the Blood an Alternative for Programmed Cell Death Ligand 1 Assessment in Non-Small Cell Lung Cancer?. <i>Cancers</i> , 2019, 11, 920.	3.7	10
36	Immunomagnetic-Enriched Subpopulations of Melanoma Circulating Tumour Cells (CTCs) Exhibit Distinct Transcriptome Profiles. <i>Cancers</i> , 2019, 11, 157.	3.7	16

#	ARTICLE	IF	CITATIONS
37	Genomic Analysis of Circulating Tumor DNA Using a Melanoma-Specific UltraSEEK Oncogene Panel. <i>Journal of Molecular Diagnostics</i> , 2019, 21, 418-426.	2.8	18
38	Incidence, features and management of radionecrosis in melanoma patients treated with cerebral radiotherapy and anti-PD-1 antibodies. <i>Pigment Cell and Melanoma Research</i> , 2019, 32, 553-563.	3.3	28
39	Circulating tumour DNA (ctDNA) as a biomarker in metachronous melanoma and colorectal cancer- a case report. <i>BMC Cancer</i> , 2019, 19, 1109.	2.6	9
40	A Panel of Circulating MicroRNAs Detects Uveal Melanoma With High Precision. <i>Translational Vision Science and Technology</i> , 2019, 8, 12.	2.2	33
41	Effectiveness of dabrafenib in the treatment of patients with BRAF V600E mutated metastatic melanoma in a Named Patient Program. <i>Melanoma Research</i> , 2019, 29, 527-532.	1.2	6
42	Programmed death ligand-1 expression in non-small cell lung cancer in a Western Australian population and correlation with clinicopathologic features. <i>Modern Pathology</i> , 2019, 32, 524-531.	5.5	13
43	Real-world efficacy and toxicity of combined nivolumab and ipilimumab in patients with metastatic melanoma. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2019, 15, 26-30.	1.1	18
44	An analysis of nivolumab-mediated adverse events and association with clinical efficacy in resected stage III or IV melanoma (CheckMate 238).. <i>Journal of Clinical Oncology</i> , 2019, 37, 9584-9584.	1.6	6
45	Monitoring melanoma recurrence with circulating tumor DNA: a proof of concept from three case studies. <i>Oncotarget</i> , 2019, 10, 113-122.	1.8	23
46	FPT155-001: A phase Ia/Ib study of FPT155 (CD80-FC) in patients with advanced solid tumors.. <i>Journal of Clinical Oncology</i> , 2019, 37, TPS42-TPS42.	1.6	1
47	A Phase I study of the novel immunomodulatory agent PG545 (pixatimod) in subjects with advanced solid tumours. <i>British Journal of Cancer</i> , 2018, 118, 1035-1041.	6.4	77
48	Clinical Application of Circulating Tumor Cells and Circulating Tumor DNA in Uveal Melanoma. <i>JCO Precision Oncology</i> , 2018, 2, 1-12.	3.0	27
49	Prognostic Relevance of CCDC88C (Daple) Transcripts in the Peripheral Blood of Patients with Cutaneous Melanoma. <i>Scientific Reports</i> , 2018, 8, 18036.	3.3	8
50	Anti-PD-1/PD-L1 immunotherapy in patients with solid organ transplant, HIV or hepatitis B/C infection. <i>European Journal of Cancer</i> , 2018, 104, 137-144.	2.8	97
51	Correlation between circulating tumour DNA and metabolic tumour burden in metastatic melanoma patients. <i>BMC Cancer</i> , 2018, 18, 726.	2.6	77
52	Medical Oncology Group of Australia position statement and membership survey on voluntary assisted dying. <i>Internal Medicine Journal</i> , 2018, 48, 774-779.	0.8	22
53	Implementation of next generation sequencing technology for somatic mutation detection in routine laboratory practice. <i>Pathology</i> , 2018, 50, 389-401.	0.6	30
54	Survey of practices around pharmaceutical company funding for continuing professional development among medical oncologists and trainees in Australia. <i>Internal Medicine Journal</i> , 2017, 47, 888-893.	0.8	8

#	ARTICLE	IF	CITATIONS
55	Reply to "Comment on "Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy". British Journal of Cancer, 2017, 116, e15-e15.	6.4	1
56	Clinical and therapeutic implications of BRAF mutation heterogeneity in metastatic melanoma. Pigment Cell and Melanoma Research, 2017, 30, 233-242.	3.3	16
57	Circulating tumour DNA (ctDNA) as a liquid biopsy for melanoma. Cancer Letters, 2017, 404, 62-69.	7.2	98
58	A first-in-human dose phase 1 study of LY3009120 in advanced cancer patients.. Journal of Clinical Oncology, 2017, 35, 2507-2507.	1.6	9
59	An open-label, multi-center phase I study of the safety and tolerability of the novel immunomodulatory agent PG545 in subjects with advanced solid tumors.. Journal of Clinical Oncology, 2017, 35, 3083-3083.	1.6	7
60	Incidence, features and management of radionecrosis (RN) in melanoma patients (pts) treated with cerebral radiotherapy (RT) and anti-PD-1 antibodies (PD1).. Journal of Clinical Oncology, 2017, 35, 9513-9513.	1.6	4
61	Updated 5-y landmark analyses of phase 2 (BREAK-2) and phase 3 (BREAK-3) studies evaluating dabrafenib monotherapy in patients with BRAF V600 mutant melanoma.. Journal of Clinical Oncology, 2017, 35, 9526-9526.	1.6	5
62	INDUCE-1: A phase I open-label study of GSK3359609, an ICOS agonist antibody, administered alone and in combination with pembrolizumab in patients with advanced solid tumors.. Journal of Clinical Oncology, 2017, 35, TPS3113-TPS3113.	1.6	8
63	Isolation and detection of circulating tumour cells from metastatic melanoma patients using a slanted spiral microfluidic device. Oncotarget, 2017, 8, 67355-67368.	1.8	45
64	Sensitive droplet digital PCR method for detection of TERT promoter mutations in cell free DNA from patients with metastatic melanoma. Oncotarget, 2017, 8, 78890-78900.	1.8	44
65	Optimizing combination dabrafenib and trametinib therapy in BRAF mutation positive advanced melanoma patients: Guidelines from Australian melanoma medical oncologists. Asia-Pacific Journal of Clinical Oncology, 2016, 12, 5-12.	1.1	22
66	A phase I dose-escalation study of BGB-A317, an anti-programmed death-1 (PD-1) mAb in patients with advanced solid tumors.. Journal of Clinical Oncology, 2016, 34, 3066-3066.	1.6	3
67	Oncologists' estimates of expected survival time and scenarios for survival: accuracy in the ALTC NITRO trial of 1st line chemotherapy for advanced non-small-cell lung cancer.. Journal of Clinical Oncology, 2016, 34, 9074-9074.	1.6	2
68	KEYNOTE-006 study of pembrolizumab (pembro) versus ipilimumab (ipi) for advanced melanoma: Efficacy by PD-L1 expression and line of therapy.. Journal of Clinical Oncology, 2016, 34, 9513-9513.	1.6	8
69	A phase I dose-escalation study of BGB-290, a novel PARP1/2 selective inhibitor in patients with advanced solid tumors.. Journal of Clinical Oncology, 2016, 34, e17049-e17049.	1.6	6
70	Circulating tumor DNA to monitor treatment response and detect acquired resistance in patients with metastatic melanoma. Oncotarget, 2015, 6, 42008-42018.	1.8	278
71	Secreted Frizzled-Related Protein 4 Inhibits Glioma Stem-Like Cells by Reversing Epithelial to Mesenchymal Transition, Inducing Apoptosis and Decreasing Cancer Stem Cell Properties. PLoS ONE, 2015, 10, e0127517.	2.5	53
72	Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial. Lancet, The, 2015, 386, 444-451.	13.7	1,175

#	ARTICLE	IF	CITATIONS
73	Patients'™ and doctors'™ preferences for adjuvant chemotherapy in resected non-small-cell lung cancer: What makes it worthwhile?. <i>European Journal of Cancer</i> , 2015, 51, 1529-1537.	2.8	23
74	Equivocal ALK fluorescence in situ hybridization (FISH) cases may benefit from ancillary ALK FISH probe testing. <i>Histopathology</i> , 2015, 67, 654-663.	2.9	15
75	Health-related quality of life impact in a randomised phase III study of the combination of dabrafenib and trametinib versus dabrafenib monotherapy in patients with BRAF V600 metastatic melanoma. <i>European Journal of Cancer</i> , 2015, 51, 833-840.	2.8	71
76	Circulating Melanoma Cell Subpopulations: Their Heterogeneity and Differential Responses to Treatment. <i>Journal of Investigative Dermatology</i> , 2015, 135, 2040-2048.	0.7	66
77	PG545 enhances anti-cancer activity of chemotherapy in ovarian models and increases surrogate biomarkers such as VEGF in preclinical and clinical plasma samples. <i>European Journal of Cancer</i> , 2015, 51, 879-892.	2.8	53
78	Mutational Analysis of BRAF Inhibitor-Associated Squamoproliferative Lesions. <i>Journal of Molecular Diagnostics</i> , 2015, 17, 644-651.	2.8	9
79	Detection of BRAF-V600E and V600K in melanoma circulating tumour cells by droplet digital PCR. <i>Clinical Biochemistry</i> , 2015, 48, 999-1002.	1.9	95
80	Overall survival in COMBI-d, a randomized, double-blinded, phase III study comparing the combination of dabrafenib and trametinib with dabrafenib and placebo as first-line therapy in patients (pts) with unresectable or metastatic BRAF V600E/K mutation-positive cutaneous melanoma.. <i>Journal of Clinical Oncology</i> , 2015, 33, 102-102.	1.6	3
81	The effects of phenoxodiol on the cell cycle of prostate cancer cell lines. <i>Cancer Cell International</i> , 2014, 14, 110.	4.1	16
82	Dose Selection, Pharmacokinetics, and Pharmacodynamics of BRAF Inhibitor Dabrafenib (GSK2118436). <i>Clinical Cancer Research</i> , 2014, 20, 4449-4458.	7.0	56
83	Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma. <i>New England Journal of Medicine</i> , 2014, 371, 1877-1888.	27.0	1,572
84	Monitoring changes in circulating tumour cells as a prognostic indicator of overall survival and treatment response in patients with metastatic melanoma. <i>BMC Cancer</i> , 2014, 14, 423.	2.6	48
85	First-in-human phase I study of a selective c-Met inhibitor volitinib (HMP504/AZD6094) in patients with advanced solid tumors.. <i>Journal of Clinical Oncology</i> , 2014, 32, 11111-11111.	1.6	10
86	COMBI-d: A randomized, double-blinded, Phase III study comparing the combination of dabrafenib and trametinib to dabrafenib and trametinib placebo as first-line therapy in patients (pts) with unresectable or metastatic BRAF ^{V600E/K} mutation-positive cutaneous melanoma. <i>Journal of Clinical Oncology</i> , 2014, 32, 9011-9011.	1.6	40
87	Randomized, double-blind phase II trial of NY-ESO-1 ISCOMATRIX vaccine and ISCOMATRIX adjuvant alone in patients with resected stage IIc, III, or IV malignant melanoma.. <i>Journal of Clinical Oncology</i> , 2014, 32, 9050-9050.	1.6	4
88	A phase 1b study of the anticancer stem cell agent demcizumab (DEM), pemetrexed (PEM), and carboplatin (CARBO) in pts with first-line nonsquamous NSCLC.. <i>Journal of Clinical Oncology</i> , 2014, 32, 2544-2544.	1.6	1
89	Advances in Personalized Targeted Treatment of Metastatic Melanoma and Non-Invasive Tumor Monitoring. <i>Frontiers in Oncology</i> , 2013, 3, 54.	2.8	27
90	An update on BREAK-3, a phase III, randomized trial: Dabrafenib (DAB) versus dacarbazine (DTIC) in patients with BRAF V600E-positive mutation metastatic melanoma (MM).. <i>Journal of Clinical Oncology</i> , 2013, 31, 9013-9013.	1.6	68

#	ARTICLE	IF	CITATIONS
91	Indwelling Pleural Catheters Reduce Inpatient Days Over Pleurodesis for Malignant Pleural Effusion. Chest, 2012, 142, 394-400.	0.8	140
92	Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet, The, 2012, 380, 358-365.	13.7	2,691
93	Phase 1 clinical trial of the novel proteasome inhibitor marizomib with the histone deacetylase inhibitor vorinostat in patients with melanoma, pancreatic and lung cancer based on in vitro assessments of the combination. Investigational New Drugs, 2012, 30, 2303-2317.	2.6	133
94	Evaluation of a multi-marker immunomagnetic enrichment assay for the quantification of circulating melanoma cells. Journal of Translational Medicine, 2012, 10, 192.	4.4	52
95	Phase 1 study of the novel vascular disrupting agent plinabulin (NPI-2358) and docetaxel. Investigational New Drugs, 2012, 30, 1065-1073.	2.6	60
96	Phase I clinical and pharmacologic study of the focal adhesion kinase (FAK) inhibitor GSK2256098 in pts with advanced solid tumors.. Journal of Clinical Oncology, 2012, 30, 3000-3000.	1.6	9
97	Phase III, randomized, open-label, multicenter trial (BREAK-3) comparing the BRAF kinase inhibitor dabrafenib (GSK2118436) with dacarbazine (DTIC) in patients with BRAF^{V600E}-mutated melanoma.. Journal of Clinical Oncology, 2012, 30, LBA8500-LBA8500.	1.6	12
98	Phase III, randomized, open-label, multicenter trial (BREAK-3) comparing the BRAF kinase inhibitor dabrafenib (GSK2118436) with dacarbazine (DTIC) in patients with BRAF^{V600E}-mutated melanoma.. Journal of Clinical Oncology, 2012, 30, LBA8500-LBA8500.	1.6	31
99	Phase II trial of BNC105P as second-line chemotherapy for advanced malignant pleural mesothelioma (MPM): Australasian Lung Cancer Trials Group and NHMRC Clinical Trials Centre Collaboration.. Journal of Clinical Oncology, 2012, 30, 7079-7079.	1.6	0
100	EGFR mutation testing in NSCLC: Patterns of care and outcomes in Western Australia. Asia-Pacific Journal of Clinical Oncology, 2009, 5, 66-71.	1.1	4
101	Phase 1 Clinical Trial of the Novel Structure Proteasome Inhibitor NPI-0052.. Blood, 2009, 114, 2693-2693.	1.4	2
102	Clinical Trial of NPI-0052 (2nd generation proteasome inhibitor) in Patients Having Advanced Malignancies with Expanded RP2D Cohorts in Lymphoma and CLL. Blood, 2008, 112, 4934-4934.	1.4	2